Tier 3 — preclinical

Pharmacokinetic properties and drug interactions of apigenin, a natural flavone

Ding Tang, Keli Chen, Luqi Huang, Juan Li
Expert Opinion on Drug Metabolism & Toxicology 2017 13(3):323-330

Bibliography

PubMed
PMID 27766890
DOI
10.1080/17425255.2017.1251903

Study snapshot

DesignNarrative review
ModelPublished apigenin pharmacokinetic and drug-interaction literature
Sample
Intervention
Duration
Endpoints

What the study showed, in plain terms

This review summarizes how apigenin is absorbed, metabolized and eliminated and why its effects on drug-metabolizing enzymes and transporters may matter for supplement-drug interactions.

Key findings

Apigenin has low oral bioavailability and undergoes extensive phase II metabolism. Experimental evidence also suggests potential interactions with metabolic enzymes and transporters, supporting caution when combined with medicines.

What this study can and cannot tell us

Many interaction findings are preclinical or in vitro. The review does not establish the magnitude or clinical significance of most interactions at supplement doses.

Citation network

Articles citing this research paper

6 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology